Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301EXT is an open-label, nonrandomized, phase 1 extension study of PSMA ADC administered IV in subjects with progressive CMPC that has progressed after prior taxane therapy. Subjects who have participated in PSMA ADC 1301 and who, in the opinion of the PI, are likely to benefit from continued treatment with PSMA ADC will be enrolled in PSMA ADC 1301EXT.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Extended 39-Week Study of PSMA ADC Following the Initial 12-Week Dose-escalation Study in Subjects With Progressive, Castration-resistant, Metastatic Prostate Cancer|
- Number of subjects with Adverse Events [ Time Frame: 39 weeks ] [ Designated as safety issue: No ]Safety and tolerability of PSMA ADC as measured by all adverse events, hematology, blood chemistry, and urine values, vital signs, electrocardiogram, and physical exam.
|Study Start Date:||January 2009|
|Study Completion Date:||November 2013|
|Primary Completion Date:||September 2013 (Final data collection date for primary outcome measure)|
|United States, New York|
|Progenics Pharmaceuticals, Inc.|
|Tarrytown, New York, United States, 10591|
|Study Director:||Robert J Israel, MD||Progenics Pharmaceuticals, Inc.|